alexa Effect of Methylprednisolone and Cyclophosphamide on the Survival of Patients with Leptospirosis, Renal Failure and Pulmonary Hemorrhage | Open Access Journals
ISSN: 2329-9088
Tropical Medicine & Surgery
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Effect of Methylprednisolone and Cyclophosphamide on the Survival of Patients with Leptospirosis, Renal Failure and Pulmonary Hemorrhage

Rudi Joy T Manipol-Larano1*, Romina A Danguilan1, Shalee Santos1, Joselito Chavez2 and Myrna T Mendoza2

1Department of Adult Nephrology, National Kidney and Transplant Institute, Philippines

2Department of Internal Medicine, National Kidney and Transplant Institute, Philippines

*Corresponding Author:
Rudi Joy T Manipol-Larano
Department of Adult Nephrology
National Kidney and Transplant Institute
East Avenue Diliman, Quezon City, Philippines
Tel: 639178814051
E-mail: [email protected]

Received Date: February 24, 2014; Accepted Date: April 24, 2014; Published Date: April 26, 2014

Citation: Manipol-Larano RJT, Danguilan RA, Santos S, Chavez J, Mendoza MT (2014) Effect of Methylprednisolone and Cyclophosphamide on the Survival of Patients with Leptospirosis, Renal Failure and Pulmonary Hemorrhage. Trop Med Surg 2:171. doi: 10.4172/2329-9088.1000171

Copyright: © 2014 Manipol-Larano RJT, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Tropical Medicine & Surgery

Abstract

Objectives: To determine the efficacy of three day methylprednisolone plus single dose intravenous
cyclophosphamide on the survival of patients with leptospirosis, renal failure and pulmonary hemorrhage.
Methods: A retrospective review of 138 patients diagnosed with leptospirosis at the National Kidney and
Transplant Institute (NKTI) from August 1, 2009 to August 31, 2013 were included in the study. Patients were grouped
according to those who received standard therapy with a 3-day course of Hydrocortisone (HC group) compared to a
3-day course of Methylprednisolone-Cyclophosphamide (MP-C). Patient survival, length of hospital stay and time to
becoming dialysis independent were compared.
Results: There were 65 patients in the HC group and 73 patients in the MP-C group. Mean age was 35.9 years,
with male predominance. The most common clinical manifestation was fever. Thrombocytopenia was the major
indication to steroid therapy. Survival of patients given MP-C was significantly higher than those given HC (88% and
74% respectively; p=0.035). The post treatment activated Plasma Thromboplastin Time (aPTT) was significantly
lower in the MP-C group. There was no significant difference in the length of hospital stay and time to becoming
dialysis independent.
Conclusion: Three day MP-C pulsing significantly improves survival of patients with leptospirosis, renal failure
and pulmonary hemorrhage.

Keywords

Leptospirosis; Weil’s disease; Renal failure; Pulmonary hemorrhage; Methylprednisolone-cyyclophosphamide pulsing; Steroids

Introduction

Leptospirosis is frequently encountered in the tropical region. It is caused by the pathogenic species of leptospira, commonly L. Interrogans, with L. icterohemorrhagica causing the severe form [1]. Leptospira-infected animals are commonly rats. They shed urine into water and soil and infect humans via skin or gastrointestinal routes. The risk of infection is increased through exposure from work, household surroundings and flooding. Clinical manifestations range from subclinical infection, self limited febrile illness to severe and fatal disease with hemodynamic collapse and multi-organ involvement, including renal and pulmonary failure [2].

Renal involvement is common in leptospirosis. Incidence of renal failure varies from 10% to over 60% [3]. The development of nephropathy is a consequence of bacterial colonization, inflammatory process, hemodynamic changes and direct toxicity of bacterial products [3]. An inflammatory process is responsible for the pathogenesis of glomerulonephritis and interstitial nephritis, involving both T helpers 1 and 2, resulting in an immune mediated nephropathy [3].

An alkaline pH caused by ammonia generation in the proximal tubules favors bacterial growth, making it the major location of leptospiral colonization [3]. Primarily, tubular degeneration involves the proximal tubules, but distal tubular necrosis occurs later [3].

Interstitial nephritis is the fundamental pathology [3]. Glomerular changes are usually unremarkable, though mesangial proliferative glomerulonephritis has been seen [4].

Pulmonary involvement occurs in 20-70% of cases and the clinical severity ranges from mild dyspnea to pulmonary hemorrhage [5].

Treatment for severe leptospirosis includes fluid resuscitation, antibiotic therapy with penicillin or ceftriaxone and supportive renal replacement therapy (RRT). Despite standard and supportive treatment, mortality still ranges from 5-20% [6,7]. Because of the more aggressive manifestations of the disease, trends in management are currently focusing on its immune aspect as a target for therapy.

In the Philippines, after the heavy rainfall of typhoon Ondoy in 2009, there was an increase in the number of patients admitted for leptospirosis with renal failure at the National Kidney and Transplant Institute (NKTI), a tertiary referral center for patients requiring renal replacement therapy (RRT). Despite standard therapy with antibiotics and dialysis, the mortality was 26% from the initial 64 patients admitted, mainly due to pulmonary hemorrhage. Due to this high mortality, the treatment protocol was revised to include a 3-day course of hydrocortisone in those with severe leptospirosis (Appendix A). An unpublished retrospective review at the NKTI looked at the effect of this short course steroid therapy on 57 patients compared to 78 patients given standard therapy alone. The mortality rate was similar among the two groups (p=0.78), although the survival time of patients who received steroids was longer (21.9 days vs 12. 7 days). The mean time to death (6.6 days) among patients who received steroids was significantly longer compared to patients on standard therapy alone (4 days) (p=0.001). In view of these findings, the short course steroid therapy was incorporated into the revised hospital protocol for the treatment of severe leptospirosis (Appendix A).

In 2012, the Monsoon rains that brought widespread flooding in Metro Manila again led to a significant increase in Leptospirosis. A total of 1,713 leptospirosis cases were reported by the department of health with 116 deaths (6.72%; range 4.5-13%) [8].

At the NKTI, 28% mortality rate was recorded among the initial 51 patients, again mainly due to pulmonary hemorrhage. Due to the very high mortality, and with the increasing trend in the use of immunosuppression in the literature, the protocol was amended to include a 3-day course of Methylprednisolone 500 mg IV followed by a single dose of Cyclophosphamide 1g/IV in cases of severe leptospirosis (NKTI 2012 leptospirosis guideline Appendix-B)

Objectives

This study aims to determine the effect of the 3-day Methylprednisolone-Cyclophosphamide in the survival of patients with severe leptospirosis, renal failure and pulmonary hemorrhage compared to those given a 3-day course of hydrocortisone. It also aims to compare the length of hospital stay, time to becoming dialysis independent and the number of fresh frozen plasma and platelet transfusions among these two groups.

Methodology

Population

Charts of patients diagnosed with leptospirosis (Based on NKTI guidelines presumptive diagnosis of leptospirosis Appendix A and B) admitted at the NKTI from September 1, 2009 to August 31, 2013 were reviewed. Sixty five patients with severe leptospirosis from Septmeber 1, 2009 to August 24, 2012 were included in the Hydrocorisone (HC) group. Seventy three patients, admitted from August 25, 2012 to August 31, 2013 composed the Methylprednisolone-Cyclosphophamide (MPC) group.

Patient demographics such as age, sex, co-morbidities, clinical presentation and baseline blood pressure were collected. Laboratoty parameters such as serum creatinine, platelet counts, PT, aPTT, chest X-ray findings and mode of renal replacement therapy of the two groups were compared.

Inclusion criteria

Patients with a presumptive diagnosis of leptospirosis who required dialysis based on clinical signs and symptoms of anuria/oliguria not responsive to hydration with creatinine of more than 3 mg/dL plus any one of the following were considered to be having severe leptospirosis:

1. Platelet count of less than 100,000×103/UL

2. Systolic Blood Pressure (SBP) less than 90 mmHg after an isotonic fluid resuscitation of 2L

3. Required inotropic support to maintain SBP >90 mmHg

4. Lung infiltrates on chest X-ray without clinical history consistent with pneumonia

5. Hemoptysis or any form of bleeding

6. Prolonged Prothrombin Time (PT-4 secs from control), and activated Plasma Thromboplastin Time (aPTT-1.5x Control)

Exclusion criteria

1. Patients who expired within 24 hours from time of admission

2. Patients who were known case of Chronic Kidney Disease

3. Patients with previous history of Acute Kidney Injury requiring RRT

4. Patients were discharged against medical advice without completing the protocol steroid therapy

Definition of Terms

Standard therapy

Penicillin G 1.5 million units Intravenous (IV) every six hours or Ceftriaxone 1 g/IV once a day, fluid hydration and/or RRT.

Hydrocortisone regimen

Hydrocortisone 200 mg IV loading dose, then 100 mg/IV every six hours for 3 days.

Methyprednisolone-cyclophosphamide regimen

Methylprednisolone 500 mg/IV Once a day for 3 days followed by a single dose of cyclophosphamide 1g/IV on the 3rd day, (cyclophosphamide can be given earlier once patient develops pulmonary hemorrhage.

Analysis of Outcomes

Primary endpoint was the overall survival of patients given MP-C compared to HC. Secondary outcomes included length of hospital stay, recovery of renal function based on the time to becoming dialysis independent, improvement of thrombocytopenia, PT and aPTT.

Statistical analysis

Sample size was computed to detect a difference in mortality of 10% between the expected group (MP-C) and the actual group (HC) using the power analysis and sample size software.

The mean and standard deviation of continuous data were computed. Frequency and percentage were used for categorical data. Z-test for two percentages was used to compare the survival of patients in the two groups. T-test was used to compare the length of hospital stay, the time to becoming dialysis independent, and the laboratory parameters among the two groups. All p-values less than 0.05 were considered significant.

Results

A total of 138 patients were included in the study, 65 patients for the HC group and 73 patients for the MP-C group. The mean age was 34.9 years, with male predominance. Most patients had no co-morbidities.

There was no significant difference in the age, sex, co-morbidities, baseline blood pressure and serum creatinine, platelet counts, PT, aPTT among the 2 groups (Table 1). All patients presented with fever. Other common signs and symptoms were calf tenderness conjunctival suffusion, and oliguria.

Parameters HC group (Mean ± SD) N= 65 MP-C group  (Mean ± SD) N=73 P value
Age (years) 35.3 ± 12.5 34.5 ± 11.1 0.83
Male
Female
58 (89%)
7 (11%)
69 (94%)
4 (7%)
0.43
Co-morbidities      
Diabetes
Hypertension
2 (3%)
3 (4%)
3 (4%)
4 (6%)
0.7
0.65
Blood Pressure(mmHg)      
Systolic
Diastolic
96.6 ± 23.4
59.53 ± 14.51
90.27 ± 18.56
57.53 ± 12.99
0.07
0.4
Initial Serum Creatinine(g/dL)  8.24 ± 5.6 8.11 ± 2.85 0.85
Initial Platelet(x 103/uL) 98.94 ± 63 112.78 ± 112.39 0.3
Initial Prothrombin Time (secs above control)  2.07 ± 1.95 1.78 ± 2.12 0.44
Initial activated Partial Thromboplastin Time (times control) 1.38 ± 0.25 1.39 ± 0.34 0.46

Table 1: Baseline Demographics, Clinical and Laboratory Profile.

Majority of patients underwent hemodialysis in both groups (71% and 84% respectively (Table 2). Chest X-ray in 22 percent of patients was normal. Among the common findings were congestion and non specific infiltrates. The most common indication to steroid therapy was thrombocytopenia (88%) and hypotension (61%).

Mode of RRT   HC group N (Percentage) N=65 MP-C N (Percentage) N=73 P value
Hemodialysis Peritoneal Dialysis 46 (71%)
19 (29%)
61 (84%)
12 (16%)
0.0657

Table 2: Mode of Renal Replacement Therapy (RRT).

Clinical Outcomes

Among the 65 patients given HC, 48 (74%) survived, while 64 patients (88%) survived in the methylprednisolone-cyclophosphamide regimen. Overall survival rate was 81%. There was statistically significant difference in patients’ survival among MP-C group compared to those in the HC group (88% vs. 74% respectively; p=0.035) (Table 3).

  Population HC MP-C z value P value
N 138 65 73 2.11 0.035*
Death 26 (19%) 17 (26%) 9 (12%)
Survived 111 (81) 48 (74%) 64 (88%)
*Statistically significant difference

Table 3: Survival of patients among the two groups.

In both groups, the most common cause of mortality was pulmonary hemorrhage (15 of the 17 deaths in the HC and 8 0f the 9 deaths in the MP-C group). The mean platelet count of those who died was below 100,000×103/UL in both groups (78.29×103/UL and 67.55×103/UL for the HC and MP-C group respectively), and was lower than those who survived (109.39×103/UL and 126.15×103/UL for the HC and MP-C group respectively). Likewise the baseline Systolic and Diastolic Blood Pressure were lower among those who died compared to the survivors (Tables 4 and 5).

Parameters HC N (percent) N=17 MP-C N (percent) N=9
Mean time to death (Days) 2.58 ± 2.26 3.22 ± 3.31
Death due to 15 (88%) 8 (88%)
Pulmonary Hemorrhage
Platelet 78.29 ± 46.83 67.55 ± 53.65
Mean + SD  (× 103/uL)
>100 × 103/uL 5 (29%) 2 (22%)
100-50 × 103/uL 6 (35%) 3 (33%)
<50 × 103/uL 6 (35%) 4 (44%)
SBP    
Mean + SD
>90mmHg
<90mmHg
85.88 ± 20.32
7 (42%)
10 (58%)
74.54 ± 15.89
3 (33%)
6 (77%)
DBP    
Mean + SD
>60mmHg
<60mmHg
52.35 ± 9.7
7 (42%)
10 (38%)
47.77 ± 10
3 (33%)
6 (77%)
Mode of RRT    
Hemodialysis
Peritoneal Dialysis
16 (94%)
1 (6%)
9 (100%)
0
Blood Transfused 6 (35%) 2 (22%)
total
FFP
Platelet
FFP + platelet

1 (6%)
3 (18%)
2 (12%)

1 (11%)
1 (11%)
0
C×R    
Infiltrates, non-specific
Congestion
No active infiltrates
10(35%)
4 (24%)
3 (18)
6 (67%)
0
3 (33%)
PT seconds above 2.91 ± 1.91 1.51 ± 1.33
control (Mean + SD)    
PTT times control 1.46 ± 0.18 1.44 ± 0.18

Table 4: Clinical and Laboratory parameters of mortality.

Parameters HC N (percent) N= 48 MP-C N (percent) N= 64
Hospital days 6.86 ± 3.77 6.44 ± 3.05
Hospital day RRT free 4.2 ± 1.68 3.95 ± 1.9
Platelet 109.39 ± 96.31 126.15 ± 83.78
Mean ± SD  (x 103/uL)
SBP 96.45 ± 23.45 95.26 ± 18.46
Mean ± SD
DBP 59.03 ± 15.35 60.78 ± 12.6
Mean ± SD
Mode of RRT 30 (62.5%)
18 (37.5%)
52 (81%)
12 (19%)
Hemodialysis
Peritoneal Dialysis
Blood Transfused total
FFP
Platelet
FFP + platelet
6 (35%)
1 (6%)
3 (18%)
2 (12%)
2 (22%)
1 (11%)
1 (11%)
0
PT seconds above 1.61 ± 1.15 2.16 ± 2.63
control (Mean + SD)
PTT times control 1.42 ± 0.23 1.41 ± 0.33

Table 5: Clinical and Laboratory parameters of Survived patients.

Three patients were complicated by Hospital Acquired Pneumonia (HAP) in the methylprednisolone group, while there were four cases of HAP in the hydrocortisone group.

There was no significant difference in the length of time of recovery (hospital days), mean time to death, time to becoming dialysis independent, post treatment values of platelet count and PT and the number of FFP and platelet concentrate among the two groups. However, the aPTT post treatment was significantly lower in those treated with MP-C than those treated with HC (P=0.018) (Table 6).

Parameters HAA( Mean ± SD) N=65 MP-C (Mean ± SD) N=73 P value
Hospital days 6.86 ± 3.77 6.44 ± 3.05 0.49
Mean time to death(days) 3.29 ± 2.61 4.33 ± 3.67 0.38
Hospital day RRT free 4.2 ± 1.68 3.95 ± 1.9 0.46
Creatinine Post treatment 2.32 ± 1.78 1.98 ± 1.19 0.21
Platelet Post treatment 253.1 ± 128.01 249 ± 131 0.78
PT post treatment (secs above control) 1.003 ± 1.28 0.87 ± 1.84 0.74
PTT post treatment
(Times control)
1.15 ± 0.23 1.04 ± 0.25 0.018*
Transfusion 20 (31%) 18 (27%)  
FFP ( Number  of patients transfused) 7 (11%) 5 1
FFP number of  units (mean ± SD) 4.8 ± 1.09 5 ± 2 0.85
Platelet  (Number of patients transfused) 10 (15%) 10 1
RBC (number of patients transfused) 3(5%) 3 1
PRBC number of  units (mean ± SD) 6.57 ± 1.51 6.2 ± 0.63 0.89
*statistically significant at 95 percent confidence interval

Table 6: Comparison of Outcomes.

Discussion

The survival of patients given the MP-C regimen was significantly higher (88%) compared to that of the HC group (74%) in our study. This finding is comparable with a recent study in India that showed an overall mortality of 18% (3 of 17) in patients who received methylprednisolone, compared to 62% (8 of 13 patients) in those who received standard therapy alone (p=0.02). In patients with established acute lung injury, five of eight patients survived in the subgroup with corticosteroids (37% mortality) while only one of nine patients survived in the standard therapy alone (89% mortality) [1].

Cyclophosphamide was likewise investigated as a treatment for leptospirosis with pulmonary hemorrhage. A study by Trivedi et al. [6] showed that among 33 patients treated with cyclophosphamide, 22 (66.7%) survived, while in 32 patients given standard therapy plus methylprednisolone alone, only three (9.4%) survived. Trivedi et al. concluded that cyclophosphamide improved survival in cases of severe alveolar hemorrhage due to leptospirosis [6]. The improvement in survival of patients using an immunosuppressive regimen, as shown in our study, further strengthens the possibility that an immune mechanism plays a key role in the pathogenesis of the disease.

Our results showed that the most common cause of mortality in both groups was pulmonary hemorrhage (88%). This is consistent with previous studies showing a poor prognosis for patients with pulmonary hemorrhage [6]. Gancheva in their study on the hemorrhagic syndrome of leptospirosis showed that hemorrhages were found in 75% of death and were risk factors for death [9]. Proposed mechanism for the pulmonary involvement includes a direct action of the bacteria on the membrane of parenchymal cells. The antigenic materials’ affinity for cell membranes suggests an interaction with surface proteins, causing functional disorders of the membranes, leading to necrosis [7]. Leptospiral toxin also causes endothelial damage to the pulmonary capillaries which can lead to generalized vasculitis [10]. Findings of antibodies and complement gives strength to the hypothesis that the infection can precipitate an immune response [11].

Majority of the patients who died had platelet counts below 100× 103/uL and lower than those who survived. Sharma in their study in 2009 concluded that thrombocytopenia was an important contributory factor in the pathogenesis of hemorrhage in leptospirosis [12]. Trevendi in 2010 also noted that there is an increase in the megakaryocytes in the bone marrow of patients with thrombocytopenia, suggesting peripheral destruction of platelets, which is most likely immune-mediated brought about by vasculitis [13]. Furthermore, the study by Gancheva et al. [9] demonstrated the presence of anti-thrombocyte antibodies causing platelet destruction in severe leptospirosis [9].

Severe vascular injury as a consequence of vasculitis can also cause destruction of the hepatic architecture, which could cause derangements in the clotting factors as manifested by prolonged PT and aPTT. Furthermore increased blood nitrogen products brought about by endothelial and tissue damage can lead to changes in the concentration of coagulation factors [9]. In the current study, the pretreatment PT and aPTT were prolonged in both groups. However, the post treatment aPTT was significantly lower in patients treated with MP-C compared to the HC group. This could have played an essential role in decreasing the hemorrhagic syndrome of patients, thus lowering mortality.

Although not statistically significant, the mean time prior to death was longer in the MP-C compared to HC group. Since infection might precipitate an inflammatory and immune response, the immunosuppression brought about by cyclophosphamide and methylprednisolone might have caused the delay in the deterioration of the patients. However, in a study in 2012 have shown that the infiltration of monocytes and neutrophils, which characterizes the inflammatory reaction, is mild compared to the vascular damage, making the pulmonary involvement primarily hemorrhagic rather than inflammatory [10]. This might have caused severe hemorrhage in some of our patients despite immunosuppression. Timing of administration of cyclophosphamide can also be an important factor. Visnith et al. [3] stated that vasculitis is often seen early in the course of the disease and is seldom seen late [3]. In our study, administration of cyclophosphamide in the protocol was after the third day of the pulsing or anytime only when the patient developed hemorrhage, which could have already been too late for some patients.

Those treated with MP-C had a shorter overall recovery period and became dialysis free earlier than those treated with HC. More patients were also transfused with fresh frozen plasma in the hydrocortisone group. However, these results were not statistically significant.

In the present study, majority of patients underwent hemodialysis in both groups (71% for HC and 84% for the MP-C), however there were more peritoneal dialysis patients in the HC group (29%) compared to those of the MP-C group (16%). Recent studies recommended the use of hemodialysis and hemofiltration in patients with leptospirosis and renal failure. But a recent review in 2011 stated that there is still room for peritoneal dialysis in management of acute kidney injury if done optimally. More studies are still needed, especially randomized control trials to fully support these conclusions. Although the difference in mode of RRT between the HC and MP-C group in our study is not statistically significant (P=0.0657), our study design cannot make conclusions on the effect of mode of renal replacement therapy on the survival of our patients, further investigation is still warranted to explore this area.

Conclusion

The three day course of methylprednisolone plus single dose intravenous cyclophosphamide significantly improves survival among patients with leptospirosis, renal failure and pulmonary hemorrhage compared to a 3-day course of hydrocortisone. There is likewise a significant improvement in the levels of aPTT in patients treated with methylprednisolone.

Recommendation

A randomized control trial should be done to determine whether MP-C significantly improves survival in severe leptospirosis, renal failure and pulmonary hemorrhage. And risk factors associated with survival such as mode of RRT should also be investigated.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 12198
  • [From(publication date):
    May-2014 - Nov 20, 2017]
  • Breakdown by view type
  • HTML page views : 8303
  • PDF downloads : 3895
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords